Cancer risk reduction using pharmacological means is an attractive modern preventive
approach that supplements the classical behavioural prevention recommendations …

The bone marrow microenvironment provides a site for cancer cells to evade systemic
anticancer therapy. Dormant tumor micrometastases are believed to be the source of …

Immune checkpoint blockade has been largely unsuccessful for the treatment of bone
metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial …

The potent anti-tumour activities of γδ T cells have prompted the development of protocols in
which γδ-agonists are administered to cancer patients. Encouraging results from small …

Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer
immunotherapy. In this study, we conducted a phase I/II clinical trial of the adoptive transfer …

Metastasis to bones is determined by both intrinsic traits of metastatic tumor cells and
properties appertaining to the bone microenvironment. Bone marrow niches are critical for …

Abstract Programmed cell death‐1 (PD‐1) is an inhibitory receptor and plays an important
role in the regulation of αβ T cells. Little is known, however, about the role of PD‐1 in γδ T …

The nitrogen-containing bisphosphonate zoledronic acid (ZOL), a potent inhibitor of farnesyl
pyrophosphate synthase, blocks the mevalonate pathway, leading to intracellular …

The acute‐phase response (APR) is the most frequent side effect after the first dose of
intravenous nitrogen‐containing bisphosphonates (N‐BPs). It has been demonstrated in …

In a study of 2005 institutionalized older people, use of oral bisphosphonates was
associated with a 27% reduction in risk of death compared to non-users after adjusting for …